Who are the leading players operating in Genotyping Assay Market?
The genotyping assay market is expected to reach USD 31.9 billion by 2023 from an estimated USD 11.8 billion in 2018, at a CAGR of 22.0%. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region
Request Sample of Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595
The demand for genome analysis in plants and animal livestock, a rising focus on national sequencing projects to establish links between genetics and disease, and the growing application areas of genotyping are expected to provide growth opportunities for players operating in the genotyping market in the coming years.
The prominent players in the genotyping assay market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).
Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five. Illumina also provides reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and other sequencing reagents, along with sequencing services such as whole-genome sequencing, human whole-exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and other related services.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595
Thermo Fisher Scientific is the second-largest player in the global genotyping market in 2018. The firm’s leading position in this market is attributed to its wide product portfolio, which includes genomic profiling, PCR, and microarray analysis instruments & reagents. The company has a wide geographic presence spanning North America, Latin America, Europe, Africa, the Middle East, and the Asia Pacific.
Recent Developments
- Agilent technologies opened a new logistics center in Texas to increase its capacity for house inventory and to fulfill the growing demand for NGS products from its genomics group.
- Danaher Corporation acquired Integrated DNA Technologies Inc. (US). This acquisition strengthened Danaher’s Life Sciences platform. IDT will operate as a standalone operating company and brand within Danaher Corporation.
- Thermo Fisher Scientific signed a partnership with Illumina (US) that enabled Illumina to sell the Ion AmpliSeq technology to researchers who conduct scientific studies using Illumina’s next-generation sequencing (NGS) platforms.
- Illumina launched the iSeq 100 Sequencing System.
- Thermo Fisher Scientific launched the Ion GeneStudio S5 Series Instrument.
Request for Custom Research @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=249958595
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian